EMD Serono and the pan-Canadian Pharmaceutical Alliance Complete Negotiations for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis

This an important next step to ensure broader access to MAVENCLAD® for eligible Canadians living with Relapsing-Remitting Multiple Sclerosis

10 Dec 2019 | MISSISSAUGA, ON, Canada

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that it completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) and signed a letter of intent (LOI) for PrMAVENCLAD® (cladribine tablets). MAVENCLAD was approved by Health Canada in November 2017 as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability.[i]      

This is an important step to ensure broader, equitable and timely access to MAVENCLAD for eligible patients across Canada.  The signed LOI allows EMD Serono, Canada to work with participating jurisdictions to implement public funding of MAVENCLAD for eligible RRMS patients, which is currently reimbursed by most private drug insurance plans.

“We’re excited to complete the pCPA negotiations and reach an agreement on the terms of public reimbursement for MAVENCLAD,” said Gaby Murphy, President & Managing Director, EMD Serono, Canada. “We look forward to working with participating jurisdictions to achieve the timely listing of MAVENCLAD by their respective public drug plans, and ensure broader access to this treatment option for Canadians living with MS.”

“Canada has one of the highest rates of MS [multiple sclerosis] in the world,” said Dr. Jiwon Oh, a Neurologist at the St. Michael’s Hospital MS Clinic in Toronto. “We are fortunate to have new and innovative MS drugs approved by Health Canada for optimal MS management. Patients need access to new treatment options, and it is encouraging that MAVENCLAD is now a step closer to being available to Canadian RRMS patients who receive their benefits from public drug plans.”

For more information or interview requests: Smita Devane-Bhan